| Name | Title | Contact Details |
|---|
Wayne Memorial Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Wayne Memorial Hospital is based in Goldsboro, NC. You can find more information on Wayne Memorial Hospital at www.waynehealth.org
Los Angeles Biomedical Research Institute is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Los Angeles Biomedical Research Institute is based in Torrance, CA. You can find more information on Los Angeles Biomedical Research Institute at www.labiomed.org
Genesis HealthCare System was created in 1997 as an affiliation between Bethesda Care System and Good Samaritan Medical Center — two health care organizations that had served the community for more than 100 years each. We are a not-for-profit organization that operates two hospital sites — Genesis-Bethesda and Genesis-Good Samaritan — in Zanesville, Ohio, and several affiliated health care organizations. By combining the resources of the two organizations, we have been able to provide several new services for the community, including open-heart surgery, a Level II neonatal intermediate care unit and enhanced cancer services. Our primary service area is a six-county region of southeastern Ohio, including Muskingum, Morgan, Perry, Coshocton, Noble and Guernsey counties.
We are a human-centered robotics company. Our mission is to make technical advances towards robots and humans working together side by side, with an emphasis on human-centric design. Diligent Robotics is developing a suite of artificial intelligence that enables robots to collaborate with and adapt to humans in everyday environments.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.